- Home
- AEVA vs NUVB Comparison
AEVA vs NUVB Comparison
Compare AEVA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- NUVB
- Stock Information
- Founded
- AEVA 2019
- NUVB 2018
- Country
- AEVA United States
- NUVB United States
- Employees
- AEVA N/A
- NUVB N/A
- Industry
- AEVA Auto Parts:O.E.M.
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- NUVB Health Care
- Exchange
- AEVA Nasdaq
- NUVB Nasdaq
- Market Cap
- AEVA 1.0B
- NUVB 1.1B
- IPO Year
- AEVA N/A
- NUVB N/A
- Fundamental
- Price
- AEVA $17.09
- NUVB $3.77
- Analyst Decision
- AEVA Strong Buy
- NUVB Strong Buy
- Analyst Count
- AEVA 5
- NUVB 7
- Target Price
- AEVA $20.80
- NUVB $8.43
- AVG Volume (30 Days)
- AEVA 2.4M
- NUVB 6.7M
- Earning Date
- AEVA 11-05-2025
- NUVB 11-05-2025
- Dividend Yield
- AEVA N/A
- NUVB N/A
- EPS Growth
- AEVA N/A
- NUVB N/A
- EPS
- AEVA N/A
- NUVB N/A
- Revenue
- AEVA $13,825,000.00
- NUVB $14,355,000.00
- Revenue This Year
- AEVA $110.19
- NUVB $332.80
- Revenue Next Year
- AEVA $96.22
- NUVB $360.12
- P/E Ratio
- AEVA N/A
- NUVB N/A
- Revenue Growth
- AEVA 111.39
- NUVB 900.35
- 52 Week Low
- AEVA $2.52
- NUVB $1.54
- 52 Week High
- AEVA $38.80
- NUVB $4.09
- Technical
- Relative Strength Index (RSI)
- AEVA 55.69
- NUVB 67.82
- Support Level
- AEVA $14.10
- NUVB $2.99
- Resistance Level
- AEVA $18.80
- NUVB $3.95
- Average True Range (ATR)
- AEVA 1.56
- NUVB 0.23
- MACD
- AEVA 0.08
- NUVB 0.04
- Stochastic Oscillator
- AEVA 59.75
- NUVB 81.25
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.